Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing

From directly observed therapy studies, urine tenofovir (TFV) levels were 74% lower when taking tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate. Urine TFV remains quantifiable across a range of TAF adherence patterns, but a separate point-of-care lateral flow immunoassay with a lower TF...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Kelly A, Niu, Xin, Glidden, David V, Castillo-Mancilla, Jose R, Yager, Jenna, MaWhinney, Samantha, Morrow, Mary, Okochi, Hideaki, Cressey, Tim R, Drain, Paul K, Gandhi, Monica, Anderson, Peter L, Spinelli, Matthew A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286091/
https://www.ncbi.nlm.nih.gov/pubmed/34285929
http://dx.doi.org/10.1093/ofid/ofab200
_version_ 1783723672990646272
author Johnson, Kelly A
Niu, Xin
Glidden, David V
Castillo-Mancilla, Jose R
Yager, Jenna
MaWhinney, Samantha
Morrow, Mary
Okochi, Hideaki
Cressey, Tim R
Drain, Paul K
Gandhi, Monica
Anderson, Peter L
Spinelli, Matthew A
author_facet Johnson, Kelly A
Niu, Xin
Glidden, David V
Castillo-Mancilla, Jose R
Yager, Jenna
MaWhinney, Samantha
Morrow, Mary
Okochi, Hideaki
Cressey, Tim R
Drain, Paul K
Gandhi, Monica
Anderson, Peter L
Spinelli, Matthew A
author_sort Johnson, Kelly A
collection PubMed
description From directly observed therapy studies, urine tenofovir (TFV) levels were 74% lower when taking tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate. Urine TFV remains quantifiable across a range of TAF adherence patterns, but a separate point-of-care lateral flow immunoassay with a lower TFV threshold will be needed to support TAF adherence monitoring.
format Online
Article
Text
id pubmed-8286091
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-82860912021-07-19 Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing Johnson, Kelly A Niu, Xin Glidden, David V Castillo-Mancilla, Jose R Yager, Jenna MaWhinney, Samantha Morrow, Mary Okochi, Hideaki Cressey, Tim R Drain, Paul K Gandhi, Monica Anderson, Peter L Spinelli, Matthew A Open Forum Infect Dis Brief Reports From directly observed therapy studies, urine tenofovir (TFV) levels were 74% lower when taking tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate. Urine TFV remains quantifiable across a range of TAF adherence patterns, but a separate point-of-care lateral flow immunoassay with a lower TFV threshold will be needed to support TAF adherence monitoring. Oxford University Press 2021-04-17 /pmc/articles/PMC8286091/ /pubmed/34285929 http://dx.doi.org/10.1093/ofid/ofab200 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Reports
Johnson, Kelly A
Niu, Xin
Glidden, David V
Castillo-Mancilla, Jose R
Yager, Jenna
MaWhinney, Samantha
Morrow, Mary
Okochi, Hideaki
Cressey, Tim R
Drain, Paul K
Gandhi, Monica
Anderson, Peter L
Spinelli, Matthew A
Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing
title Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing
title_full Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing
title_fullStr Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing
title_full_unstemmed Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing
title_short Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing
title_sort lower urine tenofovir concentrations among individuals taking tenofovir alafenamide versus tenofovir disoproxil fumarate: implications for point-of-care testing
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286091/
https://www.ncbi.nlm.nih.gov/pubmed/34285929
http://dx.doi.org/10.1093/ofid/ofab200
work_keys_str_mv AT johnsonkellya lowerurinetenofovirconcentrationsamongindividualstakingtenofoviralafenamideversustenofovirdisoproxilfumarateimplicationsforpointofcaretesting
AT niuxin lowerurinetenofovirconcentrationsamongindividualstakingtenofoviralafenamideversustenofovirdisoproxilfumarateimplicationsforpointofcaretesting
AT gliddendavidv lowerurinetenofovirconcentrationsamongindividualstakingtenofoviralafenamideversustenofovirdisoproxilfumarateimplicationsforpointofcaretesting
AT castillomancillajoser lowerurinetenofovirconcentrationsamongindividualstakingtenofoviralafenamideversustenofovirdisoproxilfumarateimplicationsforpointofcaretesting
AT yagerjenna lowerurinetenofovirconcentrationsamongindividualstakingtenofoviralafenamideversustenofovirdisoproxilfumarateimplicationsforpointofcaretesting
AT mawhinneysamantha lowerurinetenofovirconcentrationsamongindividualstakingtenofoviralafenamideversustenofovirdisoproxilfumarateimplicationsforpointofcaretesting
AT morrowmary lowerurinetenofovirconcentrationsamongindividualstakingtenofoviralafenamideversustenofovirdisoproxilfumarateimplicationsforpointofcaretesting
AT okochihideaki lowerurinetenofovirconcentrationsamongindividualstakingtenofoviralafenamideversustenofovirdisoproxilfumarateimplicationsforpointofcaretesting
AT cresseytimr lowerurinetenofovirconcentrationsamongindividualstakingtenofoviralafenamideversustenofovirdisoproxilfumarateimplicationsforpointofcaretesting
AT drainpaulk lowerurinetenofovirconcentrationsamongindividualstakingtenofoviralafenamideversustenofovirdisoproxilfumarateimplicationsforpointofcaretesting
AT gandhimonica lowerurinetenofovirconcentrationsamongindividualstakingtenofoviralafenamideversustenofovirdisoproxilfumarateimplicationsforpointofcaretesting
AT andersonpeterl lowerurinetenofovirconcentrationsamongindividualstakingtenofoviralafenamideversustenofovirdisoproxilfumarateimplicationsforpointofcaretesting
AT spinellimatthewa lowerurinetenofovirconcentrationsamongindividualstakingtenofoviralafenamideversustenofovirdisoproxilfumarateimplicationsforpointofcaretesting

Ejemplares similares